End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
273.5 TWD | -1.97% | -8.22% | +30.55% |
Mar. 14 | Alar Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 07 | Alar Pharmaceuticals Inc. Has Received Notice of Allowance for Patent in Taiwan | CI |
Sales 2022 | 800K 24.52K | Sales 2023 | 469M 14.38M | Capitalization | 11.94B 366M |
---|---|---|---|---|---|
Net income 2022 | -19M -582K | Net income 2023 | 383M 11.74M | EV / Sales 2022 | 7,589 x |
Net cash position 2022 | 484M 14.82M | Net cash position 2023 | 895M 27.42M | EV / Sales 2023 | 23.5 x |
P/E ratio 2022 |
-330
x | P/E ratio 2023 |
31.2
x | Employees | 22 |
Yield 2022 * |
-
| Yield 2023 |
0.72% | Free-Float | 57.52% |
1 day | -1.97% | ||
1 week | -8.22% | ||
Current month | -9.59% | ||
1 month | -9.59% | ||
3 months | +6.42% | ||
6 months | +31.81% | ||
Current year | +30.55% |
Managers | Title | Age | Since |
---|---|---|---|
Yung Shun Wen
CEO | Chief Executive Officer | - | 16-09-22 |
Vivian Kang
DFI | Director of Finance/CFO | - | 19-10-15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Charles Lin
CHM | Chairman | - | 16-09-22 |
Yung Shun Wen
CEO | Chief Executive Officer | - | 16-09-22 |
Cheng Yu Fang
BRD | Director/Board Member | - | 18-08-06 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-30 | 273.5 | -1.97% | 511,534 |
24-04-29 | 279 | +3.91% | 710,647 |
24-04-26 | 268.5 | -7.41% | 1,488,054 |
24-04-25 | 290 | -2.85% | 374,061 |
24-04-24 | 298.5 | -1.00% | 349,955 |
End-of-day quote Taipei Exchange, April 29, 2024
More quotes1st Jan change | Capi. | |
---|---|---|
+30.55% | 560M | |
+3.37% | 69.25B | |
+12.55% | 9B | |
-12.75% | 4.96B | |
+42.38% | 4.47B | |
+5.23% | 3.9B | |
+21.69% | 2.45B | |
-19.05% | 2.41B | |
-28.72% | 2.23B | |
+11.13% | 2.02B |
- Stock Market
- Equities
- 6785 Stock